Kangmei Pharmaceutical, con tres tableros consecutivos: actualmente, la producción y operación son normales, y la capacidad de ganancias aún necesita una mayor recuperación.

Gate.io 11th November. KANGMEI PHARMACEUTICAL announced that the closing prices of the company’s stock on 6th November 2024, 7th November 2024, and 8th November 2024 have deviated by a cumulative total of 20% for three consecutive trading days, which belongs to the abnormal fluctuation of stock trading. On 11th November 2024, the company’s stock continued to rise and reached the daily limit, with a significant short-term increase in stock price. The net profit attributable to the parent company in the first three quarters of 2024 was 5.0155 million yuan. The company’s production and operation activities are currently normal, with no major changes in its fundamentals. The profitability still needs further recovery. The Board of Directors of the company confirms that, except for the matters already publicly disclosed, as of now, the company and its controlling shareholders do not have any significant information involving the company that should be disclosed but has not been disclosed.